Back to Search Start Over

Synthesis of Recommendations From 25 Countries and 31 Oncology Societies: How to Navigate Through Covid-19 Labyrinth

Authors :
Kamposioras, K.
Mauri, D.
Papadimitriou, K.
Anthoney, A.
Hindi, N.
Petricevic, B.
Dambrosio, M.
Valachis, A.
Kountourakis, P.
Kopecky, J.
Kuhar, C.G.
Popovic, L.
Chilingirova, N.P.
Zarkavelis, G.
de Mello, R.A.
Plavetić, N.D.
Christopoulos, C.
Mostert, B. (Bianca)
Goffin, J. R.
Tzachanis, D.
Saraireh, H.H.
Ma, F
Pavese, I.
Tolia, M.
Kamposioras, K.
Mauri, D.
Papadimitriou, K.
Anthoney, A.
Hindi, N.
Petricevic, B.
Dambrosio, M.
Valachis, A.
Kountourakis, P.
Kopecky, J.
Kuhar, C.G.
Popovic, L.
Chilingirova, N.P.
Zarkavelis, G.
de Mello, R.A.
Plavetić, N.D.
Christopoulos, C.
Mostert, B. (Bianca)
Goffin, J. R.
Tzachanis, D.
Saraireh, H.H.
Ma, F
Pavese, I.
Tolia, M.
Publication Year :
2020

Abstract

Introduction: Pandemic COVID-19 is an unexpected challenge for the oncological community, indicating potential detrimental effects on cancer patients. Our aim was to summarize the converging key points providing a general guidance in order to support decision making, pertaining to the oncologic care in the middle of a global outbreak. Methods: We did an international online search in twenty five countries that have managed a surge in cancer patient numbers. We collected the recommendations from thirty one medical oncology societies. Results: By synthesizing guidelines for a) oncology service delivery adjustments, b) general and specific treatment adaptations, and c) discrepancies from guidelines comparison, we present a clinical synopsis with the forty more crucial statements. A Covid-19 risk stratification base was also created in order to obtain a quick, objective patient assessment and a risk-benefit evaluation on a case-by-case basis. Conclusions: In an attempt to face these complex needs and due to limited understanding of COVID-19, a variability of recommendations based on general epidemiological and infectious disease principles rather than definite cancer-related evidence has evolved. Additionally, the absence of an effective treatment or vaccine requires the development of cancer management guidance, capitalizing on comprehensive COVID-19 oncology experience globally.

Details

Database :
OAIster
Notes :
application/pdf, Frontiers in Oncology vol. 10, English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1244879334
Document Type :
Electronic Resource
Full Text :
https://doi.org/10.3389.fonc.2020.575148